Physician profile
James E Rocco
NPI 1710075346
$5,292.65
in general payments reported to CMS, 2019-2025
28 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $658 · 2021: $908 · 2022: $916 · 2023: $1,189 · 2024: $480 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,129.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $908.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $355.19 | 2021-2023 | |
| Abbvie INC. | $352.45 | 2021-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.07 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $300.88 | 2019-2023 | |
| Amgen INC. | $252.18 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $203.57 | 2020-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $192.60 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $153.83 | 2019-2022 | |
| Novo Nordisk INC | $145.83 | 2019-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $134.84 | 2022-2023 | Rexulti |
| Amarin Pharma, INC. | $131.61 | 2020-2021 | |
| Axsome Therapeutics, INC. | $118.58 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $101.07 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $91.22 | 2019 | |
| Xeris Pharmaceuticals, INC. | $74.18 | 2023-2025 | Gvoke Hypopen |
| Acadia Pharmaceuticals INC | $74.17 | 2022-2025 | Nuplazid |
| Merck Sharp & Dohme LLC | $60.84 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $38.94 | 2019-2020 | |
| Baxter Healthcare | $27.25 | 2023 | Hillrom - Life 2000 Ventilation System |
| Organogenesis INC. | $20.69 | 2024 | |
| Neurocrine Biosciences, INC. | $16.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.38 | 2024 | Glassia |
| Lundbeck LLC | $15.94 | 2022 | |
| Astellas Pharma US INC | $13.81 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $13.22 | 2024 | Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.